本頁只刊出中文翻譯與中文說明；英文原文請見下方原文連結。
原文連結
論文資訊
- 類型：已發表論文
- 日期：2023-03-02
摘要
A fixed one-sided significance level of 5% is commonly used to interpret the 統計 significance of randomized clinical trial (RCT) outcomes. While it is necessary to reduce the false positive rate, the threshold used could be chosen quantitatively and transparently to specifically reflect patient preferences regarding benefit-risk tradeoffs as well as other considerations. How can patient preferences be explicitly incorporated into RCTs in Parkinson's 疾病 (PD), and what is the impact on 統計 thresholds for device approval? In this analysis, we apply 貝氏 decision analysis (BDA) to PD patient preference scores elicited from survey data. BDA allows us to choose a sample size (n) and significance level (alpha) that maximizes the overall expected value to patients of a balanced two-arm fixed-sample RC
※ 此為已發表論文，全文需透過期刊付費取得